Nuts & Bolts Dealmaking
Deal-making between universities and medical device companies has historically been limited. Not only are such deals often too pricey for device companies, the nature of medical device innovation--more likely to be incremental improvements than quantum leaps forward--gives physicians and entrepreneurs an edge over universities. But that may be changing, as this look at university/medical device deals in the first half of 1997 shows.
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.
House Democrats criticized the administration’s response to the pandemic in a new report. See what Rep. James Clyburn, chairman of the Select Subcommittee on the Coronavirus Crisis, said about it here.
The Perfectio device marketer came away from the advertising industry’s self-regulatory process with a number of claims intact or mostly untouched, though it discontinued a couple going into the assessment and the National Advertising Division advised against a few others. The firm has pledged to comply “in the spirit of compromise.”